Jonathan D. Armstrong

Array ( [id] => 18288921 [patent_doc_number] => 11617778 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-04-04 [patent_title] => Ionic self-assembling peptides [patent_app_type] => utility [patent_app_number] => 16/503039 [patent_app_country] => US [patent_app_date] => 2019-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 29 [patent_no_of_words] => 22957 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16503039 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15114645 [patent_doc_number] => 20190343955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => Etanercept Formulations Stabilized with Sodium Chloride [patent_app_type] => utility [patent_app_number] => 16/456267 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16456267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15114645 [patent_doc_number] => 20190343955 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => Etanercept Formulations Stabilized with Sodium Chloride [patent_app_type] => utility [patent_app_number] => 16/456267 [patent_app_country] => US [patent_app_date] => 2019-06-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10014 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16456267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14991085 [patent_doc_number] => 20190314500 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => Etanercept Formulations Stabilized with Sodium Chloride [patent_app_type] => utility [patent_app_number] => 16/454817 [patent_app_country] => US [patent_app_date] => 2019-06-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16454817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083581 [patent_doc_number] => 20190336601 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => Etanercept Formulations Stabilized with Sodium Chloride [patent_app_type] => utility [patent_app_number] => 16/453076 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16453076 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14991083 [patent_doc_number] => 20190314499 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => Etanercept Formulations Stabilized with Sodium Chloride [patent_app_type] => utility [patent_app_number] => 16/453154 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10000 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16453154 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14991081 [patent_doc_number] => 20190314498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => Etanercept Formulations Stabilized with Sodium Chloride [patent_app_type] => utility [patent_app_number] => 16/453041 [patent_app_country] => US [patent_app_date] => 2019-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16453041 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15035741 [patent_doc_number] => 20190328875 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-31 [patent_title] => ETANERCEPT FORMULATIONS STABILIZED WITH MEGLUMINE [patent_app_type] => utility [patent_app_number] => 16/451732 [patent_app_country] => US [patent_app_date] => 2019-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9272 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16451732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213035 [patent_doc_number] => 20210346371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => METHODS OF USING SPLICING MODULATORS [patent_app_type] => utility [patent_app_number] => 17/059876 [patent_app_country] => US [patent_app_date] => 2019-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24327 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17059876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14990993 [patent_doc_number] => 20190314454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => Composition and Methods for the Treatment of Degenerative Retinal Conditions [patent_app_type] => utility [patent_app_number] => 16/401787 [patent_app_country] => US [patent_app_date] => 2019-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16401787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14715645 [patent_doc_number] => 20190248886 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-15 [patent_title] => METHODS FOR TREATING IL-6 MEDIATED INFLAMMATION WITHOUT IMMUNOSUPPRESSION [patent_app_type] => utility [patent_app_number] => 16/396378 [patent_app_country] => US [patent_app_date] => 2019-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21949 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16396378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14996285 [patent_doc_number] => 20190317100 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => LY75 AS CANCER THERAPEUTIC AND DIAGNOSTIC TARGET [patent_app_type] => utility [patent_app_number] => 16/392796 [patent_app_country] => US [patent_app_date] => 2019-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16392796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16261281 [patent_doc_number] => 10752701 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-25 [patent_title] => Stabilized formulations containing anti-PCSK9 antibodies [patent_app_type] => utility [patent_app_number] => 16/384298 [patent_app_country] => US [patent_app_date] => 2019-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19191 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16384298 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14999693 [patent_doc_number] => 20190318804 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => NANT CANCER VACCINE STRATEGIES [patent_app_type] => utility [patent_app_number] => 16/381837 [patent_app_country] => US [patent_app_date] => 2019-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29090 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 192 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16381837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14566935 [patent_doc_number] => 20190211074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => Methods for protein modification in pharmaceutical applications [patent_app_type] => utility [patent_app_number] => 16/364113 [patent_app_country] => US [patent_app_date] => 2019-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11054 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364113 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15083537 [patent_doc_number] => 20190336579 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => COMPOSITIONS AND METHODS TO INDUCE TARGETED APOPTOSIS BY MODULATING PROTEIN TYROSINE PHOSPHATASE 13 (PTPN13) [patent_app_type] => utility [patent_app_number] => 16/293248 [patent_app_country] => US [patent_app_date] => 2019-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11807 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16293248 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858526 [patent_doc_number] => 11439664 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Biologically relevant orthogonal cytokine/receptor pairs [patent_app_type] => utility [patent_app_number] => 16/289274 [patent_app_country] => US [patent_app_date] => 2019-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 36 [patent_no_of_words] => 16194 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16289274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14342267 [patent_doc_number] => 20190153106 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-23 [patent_title] => brANTI-DEspR MONOCLONAL ANTIBODY TARGETED THERAPY AND IMAGING FOR CANCER AND STROKE [patent_app_type] => utility [patent_app_number] => 16/263202 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 66663 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 164 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263202 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18545325 [patent_doc_number] => 11718665 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-08 [patent_title] => Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins [patent_app_type] => utility [patent_app_number] => 16/248629 [patent_app_country] => US [patent_app_date] => 2019-01-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 28 [patent_no_of_words] => 18785 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 202 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16248629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14652761 [patent_doc_number] => 20190233509 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => IL-6 BINDING MOLECULES [patent_app_type] => utility [patent_app_number] => 16/239321 [patent_app_country] => US [patent_app_date] => 2019-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16239321 [rel_patent_id] =>[rel_patent_doc_number] =>)